Skip to main content

Dianthus Therapeutics, Inc. (DNTH)

Sector
Healthcare
Industry
Biotechnology
Last price
$86.98
As of

Kresmion compiles this page from DNTH's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Dianthus Therapeutics, Inc. /DE/ (DNTH): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.

As of . Source: SEC EDGAR filings for DNTH. Method and limitations.

COMPANY DOSSIER

See the full DNTH dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for DNTH on one page. Preview it with sample data, then open it live with a free account.

Preview the DNTH dossier

Active events for DNTH

FREE, NO ACCOUNT

Every event on DNTH, as it fires

You are seeing 5 of 10 events recorded on DNTH since 2026-05-26.

The five above landed across 2 days. The other 5 were recorded on 2 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, DNTH

More data on DNTH

DNTH against its peers

DNTH's operating margin of -8739.3% ranks in the 9th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-09-30.

MetricDNTHPeer medianPercentilen
Revenue FY2.0M USD208M USD916
Operating margin-8739.3%-156.9%915
Net margin-7973.3%-160.6%915
Return on equity-32.9%-34.8%5022
1 year119.5%43.1%7021

Peers (25): APLS.D, GRAL, PTCT, TVTX, EWTX, ERAS, DFTX, MANE, SRRK, COGT, IONS, RLAY, MIRM, BLTE, CNTA.D, IMVT, LGND, IBRX, CRSP, ARWR, CGON, KOD, ORKA, CPRX.D, XENE. Fiscal periods ending between 2025-12-31 and 2026-09-30. Every figure is one full fiscal year read from one annual filing (DNTH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in DNTH on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DNTH in the last 180 days.

Upstream: SEC EDGAR filings for DNTH

Kresmion, "Dianthus Therapeutics, Inc. /DE/ (DNTH) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/DNTH. Upstream data: SEC EDGAR filings for DNTH.

Link to this data (HTML):

<a href="https://kresmion.com/research/DNTH">Dianthus Therapeutics, Inc. /DE/ (DNTH) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow DNTH on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DNTH for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the DNTH dossier
Share

The DNTH intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.